PRESS RELEASE 2025

Research grant empowers future leaders in clinical research to advance breakthroughs in the prevention, detection, diagnosis and treatment of NMIBC Two fellows to receive SUO NMIBC research grants through educational grant from Ferring Pharmaceuticals Schaumburg, Ill and Parsippany, NJ – December...

Parsippany, NJ – November 12, 2025 – Ferring Pharmaceuticals thanks New Jersey and Michigan for recognizing November as Clostridioides difficile (C. diff) Infection Awareness Month. The proclamations raise important awareness of the severe impact of C. diff infection, a serious and potentially de...

Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled in the ADSTILADRIN in BLadder CancEr (ABLE)-41 real-world study Independent analysis based on billin...

Analyses from the two Phase 3 RITA trials evaluate both the suitability of age-based dosing as well as the tolerability of treatment with follitropin delta in women undergoing controlled ovarian stimulation. Ferring’s long-standing commitment to helping people build families is illustrated throug...

Oral presentation highlights microbiome restoration through six months with REBYOTA from Phase 3b CDI-SCOPE trial New data from CDI-SCOPE evaluating the long-term safety of REBYOTA Retrospective analysis suggests REBYOTA continues to be effective in preventing recurrences when administered after ...

Results from two real-world studies, presented at IDWeek 2025, include initial registry findings and highlight consistent efficacy and safety of REBYOTA for preventing recurrent C. diff infection Improvements in patients’ health-related quality of life were observed in one analysis These fi...

New, real-world experience from a private clinical practice presented at the 99th Annual Meeting of the North Central Section of the American Urological Association Real-world experience showed a 77% complete response rate at three months in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive n...

TV personality Jessel Taank, Olympic gold medalist Tara Lipinski and reproductive endocrinologist Dr. Lucky Sekhon join Ferring to highlight the power of community and story sharing for aspiring parents navigating their path to parenthood Marking the birthday of Louise Brown, the first baby born ...

Data presented at Digestive Disease Week (DDW) 2025 demonstrated safety and treatment success in patients treated for recurrent C. Diff infection with REBYOTA administered by colonoscopy Data also showed improvement in quality of life and daily functioning Additional findings from the PUNCH clini...

Ferring expands production of ADSTILADRIN with new Parsippany, NJ, facility, adding to existing manufacturing sites in Kuopio, Finland Capacity expansion and diversification of manufacturing footprint further ensures stable and sustainable supply to meet the anticipated growth in global demand fo...

First results from a Phase 3 trial conducted across 25 centers in Japan highlight Ferring’s ongoing commitment to establish ADSTILADRIN as the new standard of care and backbone therapy for non-muscle invasive bladder cancer (NMIBC)1  Results showed 75% complete response rate at three months in hi...

Independent experience at three Mayo Clinic sites and real-world outcomes data with ADSTILADRIN in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented at ASCO GU 2025 Protocols for two ongoing studies from the ADSTILADRIN ...

FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA @ Home to help patients with rCDI across the U.S. receive treatment at home as well as health care sett...